# US 4,397,865 A · Method for preventing renal papillary necrosis with prostaglandins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 4,397,865 A
- Document ID: US4397865A
- Status: Granted
- Kind: A
- Application number: 06/433,587
- Filed: 1982-10-12
- Granted: 1983-08-09
- Earliest claimed: 1982-10-12
- Assignees: The Upjohn Company
- Inventors: Andre Robert; George A. Elliott
- Web page: https://patentgrep.com/patent/US4397865A

## CPC

- A61K 31/557: Eicosanoids, e.g. leukotrienes {or prostaglandins}
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a method for the prevention of renal papillary necrosis induced by non-steroidal anti-inflammatory compounds (NOSAC) comprising the administration of certain prostaglandins.

## Claims

### Claim 1

A method for the prevention of renal papillary necrosis induced by non-steroidal anti-inflammatory compounds (NOSAC) in a mammal susceptible to said necrosis comprising systemically administering to said mammal an amount of a renal cytoprotective prostaglandin effective to prevent said necrosis.

### Claim 2 (depends on 1)

A method of claim 1, wherein said mammal is not susceptible to NOSAC-induced gastrointestinal side effects.

### Claim 3 (depends on 2)

A method of claim 2, wherein said mammal is a human.

### Claim 4 (depends on 3)

A method of claim 3, wherein the renal cytoprotective prostaglandin is 16,16-dimethyl-PGE.sub.2.

### Claim 5 (depends on 3)

A method of claim 3, wherein the renal cytoprotective prostaglandin is 16,16-dimethyl PGF.sub.2 .alpha..